These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 23009940)

  • 1. Clinical predictors of outcome in MPN.
    Passamonti F; Maffioli M; Merli M; Ferrario A; Caramazza D
    Hematol Oncol Clin North Am; 2012 Oct; 26(5):1101-16. PubMed ID: 23009940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myeloproliferative neoplasms: A decade of discoveries and treatment advances.
    Tefferi A
    Am J Hematol; 2016 Jan; 91(1):50-8. PubMed ID: 26492355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long term follow up of 93 families with myeloproliferative neoplasms: life expectancy and implications of JAK2V617F in the occurrence of complications.
    Malak S; Labopin M; Saint-Martin C; Bellanne-Chantelot C; Najman A;
    Blood Cells Mol Dis; 2012 Oct 15-Dec 15; 49(3-4):170-6. PubMed ID: 22818858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of clinicopathological studies on staging and survival in essential thrombocythemia, chronic idiopathic myelofibrosis, and polycythemia rubra vera.
    Kvasnicka HM; Thiele J
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):362-71. PubMed ID: 16810612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].
    Schwarz J; Penka M; Campr V; Pospísilová D; Kren L; Nováková L; Bodzásová C; Brychtová Y; Cerná O; Dulícek P; Joniásová A; Kissová J; Korístek Z; Schützová M; Vonke I; Walterová L
    Vnitr Lek; 2011 Feb; 57(2):189-213. PubMed ID: 21416861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Dynamic International Prognostic Scoring System and MYelofibrosis SECondary to PV and ET Prognostic Model for Prediction of Outcome in Polycythemia Vera and Essential Thrombocythemia Myelofibrosis after Allogeneic Stem Cell Transplantation.
    Gagelmann N; Eikema DJ; de Wreede LC; Koster L; Wolschke C; Arnold R; Kanz L; McQuaker G; Marchand T; Socié G; Bourhis JH; Mohty M; Cornelissen JJ; Chevallier P; Bernasconi P; Stelljes M; Rohrlich PS; Fanin R; Finke J; Maertens J; Blaise D; Itälä-Remes M; Labussière-Wallet H; Robin M; McLornan D; Chalandon Y; Yakoub-Agha I; Kröger N;
    Biol Blood Marrow Transplant; 2019 Jun; 25(6):e204-e208. PubMed ID: 30930192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of peripheral blood values and bone marrow findings on prognosis for patients with essential thrombocythemia and polycythemia vera.
    Abdulkarim K; Ridell B; Johansson P; Kutti J; Safai-Kutti S; Andréasson B
    Eur J Haematol; 2011 Feb; 86(2):148-55. PubMed ID: 21059102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute transformation in nonleukemic chronic myeloproliferative disorders: actuarial probability and main characteristics in a series of 218 patients.
    Cervantes F; Tassies D; Salgado C; Rovira M; Pereira A; Rozman C
    Acta Haematol; 1991; 85(3):124-7. PubMed ID: 2042444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patients with polycythemia vera and essential thrombocythemia with prior malignancy do not have significantly worse outcome.
    Cherry M; Cardenas-Turanzas M; Pham H; Kantarjian H; Cortes J; Pierce S; Zhou L; Verstovsek S
    Leuk Res; 2013 Nov; 37(11):1472-6. PubMed ID: 23993426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups.
    Szuber N; Mudireddy M; Nicolosi M; Penna D; Vallapureddy RR; Lasho TL; Finke C; Begna KH; Elliott MA; Hook CC; Wolanskyj AP; Patnaik MM; Hanson CA; Ketterling RP; Sirhan S; Pardanani A; Gangat N; Busque L; Tefferi A
    Mayo Clin Proc; 2019 Apr; 94(4):599-610. PubMed ID: 30824279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study
    Palandri F; Palumbo GA; Iurlo A; Polverelli N; Benevolo G; Breccia M; Abruzzese E; Tiribelli M; Bonifacio M; Tieghi A; Isidori A; Martino B; Sgherza N; D'Adda M; Bergamaschi M; Crugnola M; Cavazzini F; Bosi C; Binotto G; Auteri G; Latagliata R; Ibatici A; Scaffidi L; Penna D; Cattaneo D; Soci F; Trawinska M; Russo D; Cuneo A; Semenzato G; Di Raimondo F; Aversa F; Lemoli RM; Heidel F; Reggiani MLB; Bartoletti D; Cavo M; Catani L; Vianelli N
    Semin Hematol; 2018 Oct; 55(4):248-255. PubMed ID: 30502854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of symptoms in polycythemia vera and essential thrombocythemia patients.
    Radia D; Geyer HL
    Hematology Am Soc Hematol Educ Program; 2015; 2015():340-8. PubMed ID: 26637741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progression of Myeloproliferative Neoplasms (MPN): Diagnostic and Therapeutic Perspectives.
    Baumeister J; Chatain N; Sofias AM; Lammers T; Koschmieder S
    Cells; 2021 Dec; 10(12):. PubMed ID: 34944059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Myeloproliferative disorders].
    Binder D; Fehr J
    Ther Umsch; 2004 Feb; 61(2):131-42. PubMed ID: 15018396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic factors and models in polycythemia vera, essential thrombocythemia, and primary myelofibrosis.
    Passamonti F
    Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1():S25-7. PubMed ID: 22035744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia.
    Kerbauy DM; Gooley TA; Sale GE; Flowers ME; Doney KC; Georges GE; Greene JE; Linenberger M; Petersdorf E; Sandmaier BM; Scott BL; Sorror M; Stirewalt DL; Stewart FM; Witherspoon RP; Storb R; Appelbaum FR; Deeg HJ
    Biol Blood Marrow Transplant; 2007 Mar; 13(3):355-65. PubMed ID: 17317589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
    Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W
    Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group.
    Rotunno G; Pacilli A; Artusi V; Rumi E; Maffioli M; Delaini F; Brogi G; Fanelli T; Pancrazzi A; Pietra D; Bernardis I; Belotti C; Pieri L; Sant'Antonio E; Salmoiraghi S; Cilloni D; Rambaldi A; Passamonti F; Barbui T; Manfredini R; Cazzola M; Tagliafico E; Vannucchi AM; Guglielmelli P
    Am J Hematol; 2016 Jul; 91(7):681-6. PubMed ID: 27037840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Research status and challenges of advanced myeloproliferative neoplasms].
    Bai J; Zhang YH; Shao ZH
    Zhonghua Yi Xue Za Zhi; 2023 Dec; 103(45):3603-3607. PubMed ID: 38018058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis.
    Masarova L; Bose P; Daver N; Pemmaraju N; Newberry KJ; Manshouri T; Cortes J; Kantarjian HM; Verstovsek S
    Leuk Res; 2017 Aug; 59():110-116. PubMed ID: 28601551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.